Loading...

TrovaGene

DB:XE7C
Snowflake Description

Adequate balance sheet with reasonable growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
XE7C
DB
$16M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Trovagene, Inc., a clinical-stage, oncology therapeutic company, develops drugs to treat various types of cancer, including leukemia, lymphomas, and solid tumors. The last earnings update was 48 days ago. More info.


Add to Portfolio Compare Print
  • TrovaGene has significant price volatility in the past 3 months.
XE7C Share Price and Events
7 Day Returns
12.4%
DB:XE7C
-2.7%
DE Biotechs
1.5%
DE Market
1 Year Returns
-79.6%
DB:XE7C
-10.6%
DE Biotechs
-6.2%
DE Market
XE7C Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
TrovaGene (XE7C) 12.4% 0.6% 13% -79.6% -98.8% -98.7%
DE Biotechs -2.7% 3.8% -8.5% -10.6% 47.4% 10.3%
DE Market 1.5% 6% 8.5% -6.2% 10.7% 15.3%
1 Year Return vs Industry and Market
  • XE7C underperformed the Biotechs industry which returned -10.6% over the past year.
  • XE7C underperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
XE7C
Industry
5yr Volatility vs Market
Related Companies

Value

 Is TrovaGene undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for TrovaGene. This is due to cash flow or dividend data being unavailable. The share price is €3.5.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for TrovaGene's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are TrovaGene's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:XE7C PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-8.26
NasdaqCM:TROV Share Price ** NasdaqCM (2019-04-23) in USD $3.27
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.6x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of TrovaGene.

DB:XE7C PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:TROV Share Price ÷ EPS (both in USD)

= 3.27 ÷ -8.26

-0.4x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • TrovaGene is loss making, we can't compare its value to the Europe Biotechs industry average.
  • TrovaGene is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does TrovaGene's expected growth come at a high price?
Raw Data
DB:XE7C PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.4x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
13.1%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for TrovaGene, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on TrovaGene's assets?
Raw Data
DB:XE7C PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $2.63
NasdaqCM:TROV Share Price * NasdaqCM (2019-04-23) in USD $3.27
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:XE7C PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:TROV Share Price ÷ Book Value per Share (both in USD)

= 3.27 ÷ 2.63

1.24x

* Primary Listing of TrovaGene.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • TrovaGene is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess TrovaGene's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. TrovaGene has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is TrovaGene expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
13.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is TrovaGene expected to grow at an attractive rate?
  • TrovaGene's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • TrovaGene's earnings growth is expected to exceed the Germany market average.
  • TrovaGene's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:XE7C Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:XE7C Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 13.1%
DB:XE7C Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 77.2%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:XE7C Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:XE7C Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 40 2 2
2022-12-31 2 -26 2
2021-12-31 1 -20 2
2020-12-31 1 -17 2
2019-12-31 1 -17 2
DB:XE7C Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 0 -13 -19
2018-09-30 0 -13 -18
2018-06-30 1 -16 -18
2018-03-31 1 -17 -20
2017-12-31 1 -23 -25
2017-09-30 0 -29 -31
2017-06-30 0 -29 -37
2017-03-31 0 -33 -39
2016-12-31 0 -31 -39
2016-09-30 0 -29 -38
2016-06-30 0 -27 -31
2016-03-31 0 -24 -31

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • TrovaGene's earnings are expected to grow by 13.1% yearly, however this is not considered high growth (20% yearly).
  • TrovaGene's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:XE7C Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from TrovaGene Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:XE7C Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -0.02 -0.02 -0.02 1.00
2022-12-31 -3.04 -2.07 -4.01 2.00
2021-12-31 -2.90 -1.93 -3.87 2.00
2020-12-31 -2.85 -1.67 -4.02 2.00
2019-12-31 -3.35 -2.68 -4.02 2.00
DB:XE7C Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -8.26
2018-09-30 -11.72
2018-06-30 -23.66
2018-03-31 -34.81
2017-12-31 -51.76
2017-09-30 -68.94
2017-06-30 -86.23
2017-03-31 -92.05
2016-12-31 -93.60
2016-09-30 -91.49
2016-06-30 -74.64
2016-03-31 -78.12

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if TrovaGene will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess TrovaGene's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
TrovaGene has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has TrovaGene performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare TrovaGene's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • TrovaGene does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare TrovaGene's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare TrovaGene's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
TrovaGene's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from TrovaGene Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:XE7C Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 0.38 -19.25 8.01
2018-09-30 0.49 -17.67 8.20
2018-06-30 0.52 -18.19 10.61
2018-03-31 0.51 -19.72 11.03
2017-12-31 0.51 -24.93 12.13
2017-09-30 0.39 -30.91 14.41
2017-06-30 0.35 -36.81 15.98
2017-03-31 0.36 -38.96 19.00
2016-12-31 0.38 -39.23 22.46
2016-09-30 0.39 -38.06 22.41
2016-06-30 0.36 -30.61 20.50
2016-03-31 0.31 -30.58 18.68
2015-12-31 0.31 -27.50 14.36
2015-09-30 0.29 -24.80 13.60
2015-06-30 0.29 -27.44 11.86
2015-03-31 0.30 -18.33 9.99
2014-12-31 0.28 -14.35 8.54
2014-09-30 0.27 -10.70 7.45
2014-06-30 0.26 -9.72 7.64
2014-03-31 0.25 -13.92 7.22
2013-12-31 0.26 -11.84 7.47
2013-09-30 0.38 -17.14 6.40
2013-06-30 0.54 -13.39 4.75
2013-03-31 0.54 -11.55 4.18
2012-12-31 0.45 -11.60 3.38
2012-09-30 0.32 -6.52 2.98 0.31
2012-06-30 0.16 -5.87 2.95 0.56

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if TrovaGene has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if TrovaGene has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if TrovaGene improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess TrovaGene's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
TrovaGene has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is TrovaGene's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up TrovaGene's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • TrovaGene is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • TrovaGene's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of TrovaGene's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • TrovaGene has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from TrovaGene Company Filings, last reported 3 months ago.

DB:XE7C Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 10.08 0.00 11.45
2018-09-30 13.98 0.00 15.07
2018-06-30 17.48 0.00 18.52
2018-03-31 4.68 1.17 6.66
2017-12-31 6.51 1.33 8.23
2017-09-30 3.94 1.49 7.43
2017-06-30 3.51 1.64 7.78
2017-03-31 10.68 16.57 28.80
2016-12-31 19.77 16.54 37.89
2016-09-30 26.77 16.40 46.95
2016-06-30 32.57 15.18 50.58
2016-03-31 41.16 16.22 59.99
2015-12-31 48.70 16.47 67.49
2015-09-30 54.86 15.26 74.15
2015-06-30 18.12 15.20 41.29
2015-03-31 23.56 15.08 44.00
2014-12-31 8.35 14.95 27.29
2014-09-30 12.35 14.73 31.16
2014-06-30 17.33 14.70 34.67
2014-03-31 17.75 0.48 22.87
2013-12-31 20.39 0.52 25.84
2013-09-30 21.14 0.52 27.80
2013-06-30 -2.47 0.32 8.30
2013-03-31 1.54 0.00 9.16
2012-12-31 2.17 0.00 10.82
2012-09-30 4.98 0.00 7.82
2012-06-30 5.49 0.00 9.30
  • TrovaGene has no debt.
  • TrovaGene has no debt compared to 5 years ago when it was 2.6%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • TrovaGene has less than a year of cash runway based on current free cash flow.
  • TrovaGene has less than a year of cash runway if free cash flow continues to reduce at historical rates of -22.4% each year.
X
Financial health checks
We assess TrovaGene's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. TrovaGene has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is TrovaGene's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from TrovaGene dividends.
If you bought €2,000 of TrovaGene shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate TrovaGene's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate TrovaGene's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:XE7C Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:XE7C Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as TrovaGene has not reported any payouts.
  • Unable to verify if TrovaGene's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of TrovaGene's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as TrovaGene has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess TrovaGene's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can TrovaGene afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. TrovaGene has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of TrovaGene's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Tom Adams
COMPENSATION $377,192
AGE 75
TENURE AS CEO 3.1 years
CEO Bio

Dr. Thomas H. Adams, also known as Tom, Ph.D., has been Chief Executive Officer of TrovaGene, Inc., since June 2018 and its Executive Chairman of the Board since November 2018. He served as an Interim Chief Executive Officer of TrovaGene, Inc., since June 2018 and was its Chairman of the Board since April 21, 2009 until November 2018. Dr. Adams has served as Executive Chairman of Clearbridge BioPhotonics, Pte Ltd. since April 2013 Dr. Adams served as the President of The Personalized Medicine Division at IRIS International Inc. since 2011. Dr. Adams served as the Head of Iris Molecular Diagnostics since 2006 until November 2012. Dr. Adams served as an Interim Chief Executive Officer of Trovagene, Inc. from March 28, 2016 to April 25, 2016. Dr. Adams served as the Chief Technology Officer of Iris International, Inc. since April 3, 2006 until November 2012 and served as its Corporate Vice President since April 2006. He co-founded Leucadia Technologies and served as its Chief Executive Officer and Chairman from September 1998 to April 2006. He founded Genta, Inc. in 1989. He served as the Chief Executive Officer of Iris Molecular Diagnostics. Dr. Adams served as Chief Technology Officer of IRIS from April 2006 to November 2012. He served as Chief Executive Officer of Genta, Inc. from 1989 to 1997. He Co-founded Hybritech Inc. Dr. Adams served as Senior Vice President of Research & Development and Chief Technology Officer of Hybritech from 1980 to 1984, where he achieved the first U.S. Food and Drug Administration clearance for a monoclonal antibody diagnostic product and developed the PSA test for prostate cancer, along with numerous other diagnostic products and which was later acquired by Eli Lilly and Company in 1986. He is a seasoned corporate executive and scientist with extensive medical technology experience. Dr. Adams served as Vice President of Clinical Chemistry Research and Development at Technicon Instruments Corp., and Director of Research and Development at Baxter International Inc.’s Baxter Laboratories. He has also held management positions at the Hyland Division of Baxter Travenol. He serves as Chairman Emeritus of Genta, Inc. Dr. Adams serves as Director of ContraVir Pharmaceuticals, Inc. since September 21, 2016. He served as Chairman of Iris Molecular Diagnostics. Dr. Adams founded Gen-Probe, Inc. in 1984 and served as its Chief Executive Officer and Chairman until its acquisition by Chugai Biopharmaceuticals, Inc. in 1989. Dr. Adams has been a Director of Synergy Pharmaceuticals Inc. since July 2009 and of Gensignia Life Sciences, Inc. since October 2014. He serves as a Director of Bio-Mems and Iris Molecular Diagnostics. He served as Director of La Jolla Pharmaceutical Co. from 1991 to September 03, 2009. Dr. Adams served as a Director of XiFin, Inc., since 1997; Iris International Inc., from June 10, 2005 to May 20, 2011; Biosite Diagnostics, Inc., from 1989 to 1998; Life Technologies Inc. since April 1992, Life Technologies Corporation since April 1992 and Xenomics Inc. from October 2004 to December 1, 2005. He served as a Director of Invitrogen from 2000 to 2002. He served as a Director of Used Kar Parts Inc. since October 2004. He serves as Member of Scientific Advisory Board at Tiziana Life Sciences PLC. While at Gen-Probe, he received the first FDA clearance for a DNA probe diagnostic product and received Inc. Magazine’s Product of the Year award in 1987 for a diagnostic product for Legionnaires’ disease. He is the author of numerous patents and publications in diverse areas of biomedical science. He is a recipient of Dupont Award for Technical Achievement in 1993. Dr. Adams holds a PhD in Biochemistry from the University of California at Riverside.

CEO Compensation
  • Tom's compensation has increased whilst company is loss making.
  • Tom's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the TrovaGene management team in years:

3.8
Average Tenure
  • The tenure for the TrovaGene management team is about average.
Management Team

Tom Adams

TITLE
CEO & Executive Chairman of the Board
COMPENSATION
$377K
AGE
75
TENURE
3.1 yrs

Mark Erlander

TITLE
Chief Scientific Officer
COMPENSATION
$909K
AGE
58
TENURE
6.1 yrs

Beth Anderson

TITLE
VP of Finance & Administration
TENURE
3.8 yrs

George Samuel

TITLE
VP & General Counsel

Vicki Kelemen

TITLE
Vice President of Corporate Communications
Board of Directors Tenure

Average tenure and age of the TrovaGene board of directors in years:

9
Average Tenure
68
Average Age
  • The tenure for the TrovaGene board of directors is about average.
Board of Directors

Tom Adams

TITLE
CEO & Executive Chairman of the Board
COMPENSATION
$377K
AGE
75
TENURE
10 yrs

John Brancaccio

TITLE
Director
COMPENSATION
$82K
AGE
70
TENURE
13.3 yrs

Rod Markin

TITLE
Director
COMPENSATION
$87K
AGE
61
TENURE
5.2 yrs

Gary Jacob

TITLE
Director
COMPENSATION
$66K
AGE
71
TENURE
10.2 yrs

Riccardo Dalla-Favera

TITLE
Member of Scientific Advisory Board
AGE
66
TENURE
9 yrs

Brunangelo Falini

TITLE
Member of Scientific Advisory Board
TENURE
9 yrs

Carlo Croce

TITLE
Member of Scientific Advisory Board

Paul Billings

TITLE
Member of Scientific Advisory Board
COMPENSATION
$36K
AGE
66
TENURE
6.4 yrs

Charles Cantor

TITLE
Member of Scientific Advisory Board
AGE
75

K. Hirth

TITLE
Member of Scientific Advisory Board
AGE
66
TENURE
4.7 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
09. Nov 18 Buy Rodney Markin Individual 20. Jun 18 20. Jun 18 6,867 €4.40 €30,243
14. Jun 18 Buy John Brancaccio Individual 08. Jun 18 08. Jun 18 1,667 €4.08 €6,802
14. Jun 18 Buy Stanley Tennant Individual 08. Jun 18 08. Jun 18 1,667 €4.08 €6,802
X
Management checks
We assess TrovaGene's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. TrovaGene has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Trovagene, Inc., a clinical-stage, oncology therapeutic company, develops drugs to treat various types of cancer, including leukemia, lymphomas, and solid tumors. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic Colorectal Cancer in combination with FOLFIRI and Avastin. The onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer; Phase I clinical trial with various chemotherapies and targeted therapeutics, such as Beleodaq (belinostat); Quizartinib (AC220), a development stage FLT3 inhibitor; and Velcade (bortezomib) used in leukemias, lymphomas, and solid tumor cancers. Trovagene, Inc. primarily serves pharmaceutical companies. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene, Inc. in January 2010. Trovagene, Inc. was founded in 1999 and is headquartered in San Diego, California.

Details
Name: TrovaGene, Inc.
XE7C
Exchange: DB
Founded: 1999
$14,363,670
4,922,187
Website: http://www.trovageneoncology.com
Address: TrovaGene, Inc.
11055 Flintkote Avenue,
San Diego,
California, 92121,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM TROV Common Stock Nasdaq Capital Market US USD 02. Sep 2003
DB XE7C Common Stock Deutsche Boerse AG DE EUR 02. Sep 2003
Number of employees
Current staff
Staff numbers
13
TrovaGene employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/23 20:54
End of day share price update: 2019/04/23 00:00
Last estimates confirmation: 2019/04/03
Last earnings filing: 2019/03/06
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.